Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2007

SAFC to Expand High-Potency API Manufacturing

  • SAFC reports plans for a $4.5 million capacity expansion program at its flagship SAFC Pharma high-potency API (HPAPI) facility in Madison, WI. The project, scheduled for commission in early 2008, will add cGMP pilot plant and kilo lab capacity, the company points out.

    These developments build upon existing capabilities in potent compound handling at the Safebridge®-certified SAFC Madison facility and add to a $12 million, 38,000 sq. ft. expansion program completed in 2006. Specifically, SAFC will add two 400 L cGMP pilot plant reactors and two 100 L cGMP portable jacketed reactors into a 1,200 sq. ft. dedicated, large-scale kilo lab.

    The company says that this will enable larger-scale chromatography for process purification. It also will complement the new XRPD (X-ray Powder Diffraction) analytical equipment for advanced solid form testing due to become operational this month.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »